Skyscape Web Viewer : The Maudsley Prescribing Guidelines in Psychiatry : Main Index

View All
Interactions with caffeine
interferons-a and Ã, psychiatric adverse effects
international normalised ratio (INR), psychotropic agent effects
Interpreting sample results for drugs with established target ranges
Interruptions in treatment
Interstitial lung disease
Interstitial nephritis
Interventions for non-adherence
intracranial/intracerebral haemorrhage, SSRI risks
intramuscular (IM) injections, acute behavioural disturbance
Intramuscular clozapine
Intranasal antipsychotics
Intranasal esketamine, treatment resistant depression Ketamine Management of treatment-resistant depression - other well supported treatments Official guidance on the treatment of depression
Intranasal ipratropium, clozapine-induced hypersalivation
Intranasal naloxone
Ipratropium nasal spray, clozapine-induced hypersalivation
Irritability (aggression, self-injurious behaviour, and severe disruptive behaviour), children and adolescents with autism spectrum disorder
Irritability (aggression, self-injurious behaviour, and severe disruptive behaviours) in autism spectrum disorder
Isotretinoin, psychiatric adverse effects
Ketamine anti-suicidal effects bipolar depression borderline personality disorder dosing recommendations in overdose mechanism of antidepressant action psychotic depression treatment
Ketamine as treatment Ketamine Management of treatment-resistant depression - other well supported treatments
Lack of engagement with psychological therapies
Lactate in blood, psychotropic agent effects
Lamotrigine borderline personality disorder clozapine augmentation in overdose life-threatening cutaneous reactions restarting after period of non-compliance target range
Laxative misuse/abuse Biochemical and haematological effects of psychotropics Eating disorders
Laxatives Acting on clozapine plasma concentration results Clozapine: common adverse effects Clozapine-induced gastrointestinal hypomotility Initiation of clozapine in the community Safer prescribing for physical conditions in dementia
Learning difficulties capacity and consent epilepsy comorbidity general considerations Learning disabilities prescribing practice
Legal issues
Lemborexant in overdose managing sleep disturbance in dementia use in patients with hepatic impairment
Less commonly used treatments, well supported by published evidence (no preference implied by order)